Almac and Edinburgh Instruments have announced that Astrazeneca is to carry out an evaluation of the Flexyte protein kinase assay platform.
During the evaluation period, Astrazeneca will assess the performance of the Flexyte platform in its laboratories against specific targets of interest.
Flexyte assays harness the potential of fluorescence lifetime and apply it to the process of assaying kinase activity and marks a successful collaboration between Almac Sciences, Edinburgh Instruments and Dundee University.
Avoiding radioactivity, antibodies and associated costs, fluorescent lifetime technology enables homogenous, robust and reliable assays with minimised interference from problem compounds, and will allow miniaturisation, and multiplexing, while maintaining an information-rich output.
Generic substrates enable fluorescent lifetime assays to be configured for a broad panel of Ser/Thr protein kinases in a rapid fashion, covering more than 100 different kinases - and with performance comparable to radiometric assays.
Flexyte assay reagents and protocols are available in bulk form, for high-throughput screening, or kit form, for lower-capacity assays.
